# Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

> **NCT04573309** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** ALXN1840

## Key facts

- **NCT ID:** NCT04573309
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04573309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04573309, "Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04573309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*